Status:

COMPLETED

Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine

Lead Sponsor:

International Vaccine Institute

Collaborating Sponsors:

National Institute of Hygiene and Epidemiology, Vietnam

Göteborg University

Conditions:

Cholera

Eligibility:

All Genders

18-40 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of a new formulation of a locally-produced bivalent, (O-1 and O-139) killed whole cell oral cholera vaccine among Vietnamese adul...

Detailed Description

Cholera remains to be a serious public health problem worldwide. In the mid-1980s following technology transfer from Sweden, Vietnamese scientists developed and produced an oral killed monovalent chol...

Eligibility Criteria

Inclusion

  • Healthy non-pregnant adults
  • Available in the study area for 1 month

Exclusion

  • Diarrhea for the past week
  • Antibiotic use in the past week
  • Intake of anti-diarrheal medicines in the past week
  • One or more episodes of diarrhea or abdominal pain lasting for 2 weeks during the past 6 months
  • Abdominal pain, nausea, vomiting, loss of appetite or generalized ill feeling for the past 24 hours
  • Pregnancy

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

End Date :

June 1 2005

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00128011

Start Date

May 1 2005

End Date

June 1 2005

Last Update

November 10 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Institute of Hygiene and Epidemiology

Hanoi, Vietnam, 10000

Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine | DecenTrialz